Alzheimer's disease (AD) is a form of dementia in which patients develop neurodegeneration and complete loss of cognitive abilities and die prematurely. No treatment is known for this condition. Evidence points toward ␤-amyloid as one of the main causes for cytotoxic processes. The cascade of biochemical events that lead to neuronal death appears to be interference with intracellular calcium homeostasis via activation of calcium channels, intracellular calcium stores, and subsequent production of free radicals by calcium-sensitive enzymes. The glutamatergic system seems to be implicated in mediating the toxic processes. Several strategies promise amelioration of neurodegenerative developments as judging from in vitro experiments. Glutamate receptor-selective drugs, antioxidants, inhibitors of nitric oxide synthase, calcium channel antagonists, receptor or enzyme inhibitors, and growth factors promise help. Especially combinations of drugs that act at different levels might prolong patients' health. 1998 Academic Press
Alzheimer's disease (AD) is a form of dementia that invariably leads to complete loss of all cognitive abilities and premature death. No treatment is known for this condition. In the United States, a communitybased study has suggested that approximately 4 million people have AD (Evans et al., 1989) . The prevalence of AD is 3% for persons 65-74 years old, 18.7% for those 75-84 years old, and 47.2% for those over 85 years old (Katzman, 1976) . With the aging of society it has been estimated that approximately 9 million individuals in the United States could develop AD by the year 2040, unless preventive strategies are found (National Institute on Aging, 1995).
The main symptoms for AD are the presence of senile plaques, silver positive neurofibrillary tangles (NFT), and prominent cortical neuron loss. The causes for these developments are still not entirely understood even though a considerable amount of detailed knowledge has accumulated over the past 30 years.
Currently, drugs used to treat AD strategies act mainly on the acetylcholine neurotransmitter system, such as the acetylcholine esterase inhibitors Tacrine, Velnacrine, or Aricept, since it was believed until recently that the main cause for AD is a degeneration of basal brain nuclei that use acetylcholine as a neurotransmitter (Gooch and Stennett, 1996; Shintani and Uchida, 1997) . These drugs only show limited effect (Weiner, 1997) and it is possible that upregulation of a degenerating system might speed up neurotoxic processes. Activation of acetylcholinergic neurons increases the release of amyloid precursor molecules (Nitsch et al., 1992) and could increase production of ␤-amyloid. However, focus of research has shifted over the years toward glutamatergic neurodegeneration which appears to explain the physiological and anatomical hallmarks of AD better (Masliah et al., 1996; Braak and Braak, 1997; Arendt et al., 1998) .
